Header5

The simple corporate scheme behind massive US Brand Drug Prices

My 7-year whistleblower effort
"People Before Profits"

U.S. Rheumatoid Arthritis/Autoimmune Market

Amgen's Enbrel and AbbVie's Humira

U.S. Rheumatoid Arthritis/Autoimmune Market 

  • Uniform massive 5-7 fold U.S. price increases in the decade-plus since Medicare Part D began
    • from about $15,000 patient/year before Part D to the $75,000 patient/year range now
  • Despite rising competition from numerous similar new drugs reaching the U.S market

Amgen’s Enbrel (on U.S. market since 1997)

  • 2005 Reported U.S. Sales: $2.47 billion
  • 2017 Reported U.S. Sales: $5.2 billion
  • U.S. Clinical Use/Prescriptions DOWN -25% since 2005
  • 2017 U.S. Sales WITHOUT Price Increases: $1.9 billion
  • 2005 U.S. “List”/“Sticker”: $15,000/patient/year
  • 2018 U.S. “List”/“Sticker”: $75,000/patient/year
  • Cumulative harm since start of Part D: $19.1+ billion

Abbvie’s Humira (on U.S. market since 2003)

  • 2005 Reported U.S. Sales: $560 million
  • 2017 Reported U.S. Sales: $12.4 billion
  • 2017 U.S. Sales WITHOUT Price Increases: $3.8 billion
  • 2005 U.S. “List”/“Sticker”: $15,000/patient/year
  • 2018 U.S. “List”/“Sticker”: $75,000/patient/year
  • Cumulative harm since start of Part D: $32.3+ billion

 

Receive the Latest News

Your email is 100% safe.
Your privacy will be respected.
!
!
Something went wrong. Please check your entries and try again.
Scroll to Top